Germany · Delayed Price · Currency is EUR Formycon AG Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw revenues more than double year-over-year, driven by FYB202 and FYB206, with EBITDA losses narrowing sharply. Key launches and partnerships expanded the commercial portfolio, and guidance for 2026 is confirmed, with growth expected from milestone achievements and royalties.
Fiscal Year 2025
-
2025 saw a strategic transformation with improved adjusted EBITDA and strong cost management, despite lower revenues. 2026 guidance anticipates significant revenue growth, driven by FYB202 royalties and FYB206 milestones, with positive EBITDA expected.
-
Full-year guidance is reaffirmed with a strong Q4 expected, driven by FYB202 royalties and anticipated FYB206 licensing deals. Operational cost reductions and a robust cash position support ongoing pipeline development, while regulatory changes and strategic partnerships position the company for future growth.
-
Full-year revenue and EBITDA guidance are reaffirmed, with a significant revenue ramp expected in Q4 2025 from FYB202 royalties and FYB206 licensing. Operational momentum is strong, supported by new product launches, a successful bond placement, and a robust pipeline.
-
Q1 2025 saw revenues decline year-over-year due to milestone timing and US market headwinds, but operational execution remained strong and full-year guidance is confirmed. Major revenue growth is expected in H2, driven by FYB202 launches and licensing, with a robust cash position maintained.
-
Strategic adjustments are underway for U.S. commercialization of FYB201 and FYB202 due to evolving market dynamics, with significant non-cash impairments expected but no impact on key financial KPIs. The FDA's Phase III waiver for FYB206 streamlines development and reduces costs, supporting long-term growth and financial stability.
Fiscal Year 2024
-
Exceeded 2024 guidance with strong pipeline progress and key regulatory approvals. 2025 outlook anticipates stable revenues, continued investment in biosimilars, and EBITDA profitability by 2026, despite U.S. market headwinds and asset impairments.
-
Strong operational and financial performance marked by multiple regulatory approvals, increased royalty revenues, and robust pipeline expansion. Guidance for 2024 is confirmed, with key launches and partnerships expected in 2025.
-
H1 2024 saw strong operational and financial performance, with key regulatory milestones achieved and robust sales in major markets. Guidance for adjusted EBITDA and working capital was raised, supported by a strengthened balance sheet and continued pipeline progress. FYB201 and FYB202 remain growth drivers.